Scientists have found an antibody, a monthly dose of which could halve the number of debilitating attacks of a migraine on patients who have exhausted all other treatments.The findings showed that people treated with erenumab were nearly three times more likely to have reduced their migraine days by 50 percent or more than those treated with placebo. Those treated with erenumab also had a greater average reduction in the number of days they had headaches and the number of days they needed to take drugs to stop the migraines. "Our study found that erenumab reduced the average number of monthly migraine headaches by more than 50 percent for nearly a third of study participants.
That reduction in migraine headache frequency can greatly improve a person's quality of life," said a researcher from The Charite - University Medicine Berlin in Germany. Erenumab is a monoclonal antibody that…
